Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.
2.

Cardiac differentiation of pluripotent stem cells.

Rajala K, Pekkanen-Mattila M, Aalto-Setälä K.

Stem Cells Int. 2011;2011:383709. doi: 10.4061/2011/383709. Epub 2011 Apr 4.

3.

Ginsenoside Rg(3) decelerates hERG K(+) channel deactivation through Ser631 residue interaction.

Choi SH, Shin TJ, Hwang SH, Lee BH, Kang J, Kim HJ, Jo SH, Choe H, Nah SY.

Eur J Pharmacol. 2011 Aug 1;663(1-3):59-67. doi: 10.1016/j.ejphar.2011.05.006. Epub 2011 May 11.

PMID:
21586280
4.

Modelling the long QT syndrome with induced pluripotent stem cells.

Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L.

Nature. 2011 Mar 10;471(7337):225-9. doi: 10.1038/nature09747. Epub 2011 Jan 16.

PMID:
21240260
5.

Quantitative prediction of the arrhythmogenic effects of de novo hERG mutations in computational models of human ventricular tissues.

Benson AP, Al-Owais M, Holden AV.

Eur Biophys J. 2011 May;40(5):627-39. doi: 10.1007/s00249-010-0663-2. Epub 2011 Jan 14.

PMID:
21234558
6.

Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits.

Bentzen BH, Bahrke S, Wu K, Larsen AP, Odening KE, Franke G, Storm vańs Gravesande K, Biermann J, Peng X, Koren G, Zehender M, Bode C, Grunnet M, Brunner M.

J Cardiovasc Pharmacol. 2011 Feb;57(2):223-30. doi: 10.1097/FJC.0b013e318203a44d.

PMID:
21135701
7.

Effects of late sodium current enhancement during LQT-related arrhythmias. A simulation study.

Cardona K, Trenor B, Rajamani S, Romero L, Ferrero JM, Saiz J.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:3237-40. doi: 10.1109/IEMBS.2010.5627184.

PMID:
21096605
8.

Nicorandil normalizes prolonged repolarisation in the first transgenic rabbit model with Long-QT syndrome 1 both in vitro and in vivo.

Biermann J, Wu K, Odening KE, Asbach S, Koren G, Peng X, Zehender M, Bode C, Brunner M.

Eur J Pharmacol. 2011 Jan 10;650(1):309-16. doi: 10.1016/j.ejphar.2010.10.016. Epub 2010 Oct 17.

9.

Patient-specific induced pluripotent stem-cell models for long-QT syndrome.

Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, Dorn T, Goedel A, Höhnke C, Hofmann F, Seyfarth M, Sinnecker D, Schömig A, Laugwitz KL.

N Engl J Med. 2010 Oct 7;363(15):1397-409. doi: 10.1056/NEJMoa0908679. Epub 2010 Jul 21.

10.

Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: evidence for clinically significant IKr-IKs alpha-subunit interaction.

Biliczki P, Girmatsion Z, Brandes RP, Harenkamp S, Pitard B, Charpentier F, Hébert TE, Hohnloser SH, Baró I, Nattel S, Ehrlich JR.

Heart Rhythm. 2009 Dec;6(12):1792-801. doi: 10.1016/j.hrthm.2009.08.009. Epub 2009 Aug 13.

PMID:
19959132
11.

The genetic basis of long QT and short QT syndromes: a mutation update.

Hedley PL, Jørgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA, Christiansen M.

Hum Mutat. 2009 Nov;30(11):1486-511. doi: 10.1002/humu.21106. Review.

PMID:
19862833
12.

Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).

Gerlach AC, Stoehr SJ, Castle NA.

Mol Pharmacol. 2010 Jan;77(1):58-68. doi: 10.1124/mol.109.059543. Epub 2009 Oct 5.

13.

Electrophysiologic characterization of a novel hERG channel activator.

Su Z, Limberis J, Souers A, Kym P, Mikhail A, Houseman K, Diaz G, Liu X, Martin RL, Cox BF, Gintant GA.

Biochem Pharmacol. 2009 Apr 15;77(8):1383-90. doi: 10.1016/j.bcp.2009.01.015. Epub 2009 Feb 3.

PMID:
19426677
14.

Discovery of a novel activator of KCNQ1-KCNE1 K channel complexes.

Mruk K, Kobertz WR.

PLoS One. 2009;4(1):e4236. doi: 10.1371/journal.pone.0004236. Epub 2009 Jan 21.

15.

Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome.

Brunner M, Peng X, Liu GX, Ren XQ, Ziv O, Choi BR, Mathur R, Hajjiri M, Odening KE, Steinberg E, Folco EJ, Pringa E, Centracchio J, Macharzina RR, Donahay T, Schofield L, Rana N, Kirk M, Mitchell GF, Poppas A, Zehender M, Koren G.

J Clin Invest. 2008 Jun;118(6):2246-59. doi: 10.1172/JCI33578.

16.
17.

A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response.

Bankston JR, Yue M, Chung W, Spyres M, Pass RH, Silver E, Sampson KJ, Kass RS.

PLoS One. 2007 Dec 5;2(12):e1258.

18.

Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643).

Hansen RS, Diness TG, Christ T, Demnitz J, Ravens U, Olesen SP, Grunnet M.

Mol Pharmacol. 2006 Jan;69(1):266-77. Epub 2005 Oct 11.

19.

Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.

Zhou J, Augelli-Szafran CE, Bradley JA, Chen X, Koci BJ, Volberg WA, Sun Z, Cordes JS.

Mol Pharmacol. 2005 Sep;68(3):876-84. Epub 2005 Jun 23.

20.

K(ATP) channel therapeutics at the bedside.

Jahangir A, Terzic A.

J Mol Cell Cardiol. 2005 Jul;39(1):99-112. Review.

Supplemental Content

Support Center